Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a collaboration and license agreement. This pact centers around ADLARITY (donepezil transdermal system), an unprecedented Alzheimer’s dementia therapy, targeting ten key Asian markets. ADLARITY, hailed as the U.S. Food and Drug Administration’s first-ever once-weekly patch to address mild […]
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer’s type by randomizing the first patient. According to the Indian biopharma company, the late-stage trial of the serotonin-6 (5-HT6) receptor antagonist is a double-blind, placebo-controlled study intended to be held in 50 sites in North America and […]
MGC Pharmaceuticals, a developer of phytocannabinoid-derived medicines, has signed a $24 million supply and distribution deal with US-based AMC Holdings. The deal is for the supply of the company’s products, which include epilepsy candidate CannEpil, dementia and Alzheimer’s candidate CogniCann, and CimetrA over an initial three-year period. MGC Pharmaceuticals said that this is its maiden […]
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias. The Indian biopharma company expects to enroll patients from mid-September. Masupirdine is a selective, brain penetrant and orally active, chemical entity. Its late-stage study to be […]
Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US pharma giant said that the deal gives it a new modality for drug discovery and development. Furthermore, it will extend its research efforts via the creation of a gene therapy […]
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease and other dementias. NeuroLucent is currently developing novel small molecule compounds that normalize a key calcium channel that is dysregulated in Alzheimer’s disease’s neurons and restore normal neuronal function in […]
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease and other dementias. NeuroLucent is currently developing novel small molecule compounds that normalize a key calcium channel that is dysregulated in Alzheimer’s disease’s neurons and restore normal neuronal function in […]
As per the recent study published in journal of Nutrition, daily intake of fruits like orange and grapes by the adults can cut the risk of dementia by 23 percent. Researchers in Japan from Tohuku University found that if adults consume any citrus fruits like oranges, grapes, lemons or lime daily can reduce the chances […]
